You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Takeda reported six-month revenue of JPY 2,407.0 billion and net profit of JPY 305.7 billion for the period ended September 30, 2026. ORZEYFUL received U.S., Japan and China approvals, MIMRYLO won U.S. approval, and arcotatug tavatecan met primary endpoints.
Takeda reported September 30, 2026 six-month revenue of JPY 2,407.0 billion (+8.4% AER) and operating profit of JPY 406.7 billion (+60.4% AER). FY2026 revenue forecast was revised to JPY 4,700.0 billion; a JPY 102 per-share interim dividend was approved.
Useful current figures from the complete screener profile.
Hims & Hers closed at $32.84, off 50.4% from its 52-week high, with short interest at 26.4% of shares outstanding and the steepest positioning in the comp set against a +59.0% TTM revenue base and a 10%–12% full-year adjusted EBITDA guide — the next quarter decides whether the multiple re-rates with subscriber growth or compresses further on the 6% ARPU slide.
A $413.3M small-cap MCM franchise that has signed a $140M Canada agreement, a $54M ASPR award, and an ACAM2000 modification while net leverage fell to 1.9x and a $50M buyback was reauthorized — yet the equity is the worst YTD performer in the peer set with 19.9% short interest, leaving the print of the next four quarters to test whether the international MCM pivot can offset the Narcan generics drag.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TAK
this stock
Takeda Pharmaceutical Co Ltd
|
$68.47B | +37.5% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$53.23B | +10.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$51.92B | +42.6% | +4.3% | 101.1 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$40.25B | -9.3% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Takeda reported six-month revenue of JPY 2,407.0 billion and net profit of JPY 305.7 billion for the period ended September 30, 2026. ORZEYFUL received U.S., Japan and China approvals, MIMRYLO won U.S. approval, and arcotatug tavatecan met primary endpoints.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TAK | +2.0% | +9.0% | +35.0% | +2.5% | +37.5% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -0.6% | +10.1% | +34.5% | +2.7% | +26.8% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
